This company listing is no longer active
Resumen de acción KA6N
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Competidores de Karo Pharma AB (publ)
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.44 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$4.57 |
| Beta | 0.10 |
| 1 Month Change | 0.37% |
| 3 Month Change | -1.81% |
| 1 Year Change | -2.68% |
| 3 Year Change | 48.31% |
| 5 Year Change | 40.68% |
| Change since IPO | -99.42% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| KA6N | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 0.7% | 1.5% | -1.0% |
| 1Y | -2.7% | -26.5% | 2.2% |
Rentabilidad vs. Industria: KA6N exceeded the German Pharmaceuticals industry which returned -8.8% over the past year.
Rentabilidad vs. Mercado: KA6N exceeded the German Market which returned -16.6% over the past year.
Volatilidad de los precios
| KA6N volatility | |
|---|---|
| KA6N Average Weekly Movement | 1.9% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: KA6N has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: KA6N's weekly volatility (2%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 225 | Christoffer Lorenzen | www.karopharma.com |
Resumen de fundamentos de Karo Pharma AB (publ)
| Estadísticas fundamentales de KA6N | |
|---|---|
| Capitalización bursátil | €15.95b |
| Beneficios(TTM) | -€189.85m |
| Ingresos (TTM) | €3.47b |
0.0x
Ratio precio-ventas (PS)0.0x
Ratio precio-beneficio (PE)¿Está KA6N sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de KA6N | |
|---|---|
| Ingresos | kr3.47b |
| Coste de los ingresos | kr1.50b |
| Beneficio bruto | kr1.96b |
| Otros gastos | kr2.15b |
| Beneficios | -kr189.85m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.69 |
| Margen bruto | 56.67% |
| Margen de beneficio neto | -5.48% |
| Ratio deuda/patrimonio | 104.8% |
¿Cómo se ha desempeñado KA6N a largo plazo?
Ver rendimiento histórico y comparativa